Overview

This trial is active, not recruiting.

Conditions mucopolysaccharidosis (mps), hunter syndrome
Sponsor Shire
Start date January 2013
End date October 2016
Trial size 100 participants
Trial identifier NCT01822184, HGT-HIT-090

Summary

Hunter syndrome (Mucopolysaccharidosis II, [MPS II]) is a rare, genetically linked lysosomal storage disease (LSD) caused by deficiency of the enzyme, iduronate-2-sulfatase (I2S). Most MPS II patients will present with some degree of neurodevelopmental involvement, ranging from severe cognitive impairment and behavioral problems to mildly impaired cognition. This is an observational study; no investigational treatment will be administered. The primary objective of this study is to evaluate the neurodevelopmental status of pediatric patients with MPS II over time and to gain information to guide future treatment studies in this patient population.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Observational non-treatment study

Primary Outcomes

Measure
Neurodevelopmental parameters of cognitive function over time in pediatric patients with MPS II
time frame: 24 months
Neurodevelopmental parameters of adaptive function over time in pediatric patients with MPS II
time frame: 24 months

Secondary Outcomes

Measure
Reported adverse events
time frame: 24 months
Medication usage
time frame: 24 months
Quality of life
time frame: 24 months

Eligibility Criteria

Male participants from 2 years up to 18 years old.

Inclusion Criteria: Patients must meet all of the following criteria to be considered eligible for enrollment: 1. a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity AND b. The patient has a documented mutation in the iduronate-2-sulfatase gene. OR c. The patient has a normal enzyme activity level of one other sulfatase 2. The patient is male, and is at least 2 years of age and less than 18 years of age at the time of informed consent. 3. The patient must have sufficient auditory capacity at enrollment, with or without hearing aids, in the Investigator's judgment to complete the required protocol testing, and be compliant with wearing the aids on scheduled study visits. 4. The patient, patient's parent(s), or legally authorized guardian(s) has voluntarily signed an Institutional Review Board / Independent Ethics Committee-approved informed consent and/or assent form(s), as applicable. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from the study. 1. The patient has clinically significant non-Hunter syndrome-related CNS involvement or medical or psychiatric comorbidity(ies) which, in the investigator's judgment, may interfere with the accurate administration and interpretation of protocol assessments, affect study data, or confound the integrity of study results. 2. The patient has a general conceptual ability score (GCA) or a developmental quotient on the cognitive scale below 55 at Screening. 3. The patient is participating in an interventional clinical trial or has participated in an interventional clinical trial within 30 days prior to enrollment; participation in non interventional observational studies is permitted.

Additional Information

Official title A Prospective, Longitudinal, Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Shire.